
|Articles|July 26, 2022
Daily Medication Pearl: Tapinarof (Vtama)
Author(s)Saro Arakelians, PharmD
Tapinarof (Vtama) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Advertisement
Medication Pearl of the Day: Tapinarof (Vtama)
Indication: Tapinarof (Vtama) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.
Insight:
- Dosing: Apply a thin layer of tapinarof cream to affected areas once daily.
- Dosage forms: Cream, 1%- each gram of tapinarof cream contains 10 mg of tapinarof.
- Adverse events: Most common adverse reactions (incidence ≥ 1%) in patients treated with tapinarof cream were folliculitis, nasopharyngitis, contact dermatitis, headache, pruritus, and influenza.
- Mechanism of action: Tapinarof is an aryl hydrocarbon receptor agonist. The specific mechanisms by which tapinarof cream exerts its therapeutic action in psoriasis patients are unknown.
Source: https://www.vtama.com/hcp/PI/
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
IRAKLIA Trial Shows Body Weight Doesn’t Alter Outcomes With On-Body Injector Isatuximab
2
2025 FDA Approvals Highlight the Growing Role of Biomarkers in Breast Cancer
3
SABCS 2025 Roundup: Advancing Therapy and Precision Care in Breast Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5

















































































































































































































